Preventing postoperative complications in patients undergoing high-risk pancreatoduodenectomy with a bundle approach including hydrocortisone, ocreotide, and teres ligament patch (PANENCA): an international randomized controlled multicenter trial

Brief summary (registry, in English)

The primary aim of the PANENCA trial is to investigate the effect of a combined treatment with hydrocortisone, octreotide, teres patch (HOP bundle) on major complications after pancreatoduodenectomy

What you commit to

• Study type: Interventional · Phase 4
• Planned participants: 460
• 24 sites in 7 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults who will have planned surgery to remove part of the pancreas (pancreatoduodenectomy) and who have a narrow pancreatic duct.

Age

Over 18 years

Sex

All sexes

Disease stage

Planned pancreatoduodenectomy for any reason, open or minimally invasive surgery. Pancreatic duct width of 3 mm or less on a CT or MRI scan before surgery.

Main reasons for not taking part

• Under 18 years old
• Pregnant
• Known allergy to hydrocortisone or octreotide
• Fungal infection throughout the body
• Taking CYP3A4 inhibitor or inducer drugs

Read by machine on 9 Nov 2026.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (24)

Sites in registry order. Save your city in your profile to sort them by distance.

Are you the coordinator? Confirm the details